Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jnci/djt451 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world clinical practice: exploring the positive effect of combination with erythropoietin alfa.
Front Oncol
October 2024
Center of Oncocytogenomics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czechia.
Background: Luspatercept, an inhibitor of the transforming growth factor beta (TGF-β) pathway, is a novel treatment for anemic patients with lower-risk myelodysplastic syndromes (MDS) with transfusion dependence (TD) who do not respond to erythropoiesis-stimulating agents (ESA) therapy or are not suitable candidates for this treatment. We present real-world experience with luspatercept therapy from two hematology centers in the Czech Republic.
Methods: By January 2024, 54 MDS patients (33 men, 21 women) with a median age of 74 years (range, 55-95) were treated with luspatercept ± ESA at two Charles University hematology centers in Prague and Hradec Králové.
Rhabdomyolysis caused by interaction between rosuvastatin and vadadustat: a case control study.
J Pharm Health Care Sci
April 2023
Department of Neurosurgery, Aso Medical Center, 1266 Kurokawa, Aso-Shi, Kumamoto-ken, 869-2225, Japan.
Article Synopsis
- Rhabdomyolysis is a serious condition caused by muscle cell damage, leading to dangerous substances entering the bloodstream; this study examines a case where the interaction of the drugs rosuvastatin and vadadustat possibly caused this condition.
- A 62-year-old male with multiple health issues experienced a sharp increase in creatine phosphokinase (CPK) levels, indicating muscle damage after switching to vadadustat while on rosuvastatin for treatment.
- The patient's treatment plan was adjusted, leading to improvements in muscle and kidney function after discontinuing the problematic medications, allowing him to be discharged with a lower dose of rosuvastatin.
Epoetin alfa biosimilar (HX575): A review of 15 years' post-approval clinical experience.
Crit Rev Oncol Hematol
January 2023
Sandoz GmbH, Holzkirchen, Germany.
Biosimilars offer the potential to expand patient access and reduce healthcare costs. Therefore, it is of importance that clinicians and patients are reassured about their efficacy and safety in practice. In 2007, Binocrit® (HX575; Sandoz GmbH, Kundl, Austria) was the first epoetin alfa biosimilar approved for use in chemotherapy induced anaemia (CIA), chronic renal failure (CRF), and more recently myelodysplastic (MDS) anaemia.
View Article and Find Full Text PDFThe Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
BioDrugs
July 2022
Clinical Pharmacy Group, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Länsisatamankatu 24 A 5, 00220, Helsinki, Finland.
Article Synopsis
- Biological drugs are very expensive and critical for treating chronic diseases, but biosimilars, which are similar to these drugs, can help lower costs.
- The study focused on how the introduction of biosimilars in Finland between 2009 and 2020 affected the prices of original biological products and the overall competition in the biological drug market.
- Findings revealed that the prices of reference products usually decreased when biosimilars entered the market, while biosimilar prices remained relatively stable, highlighting their role in influencing healthcare costs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!